NCT02558868

Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer

Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Advanced Pancreatic Cancer Patients Progressed After First-line Gemcitabine and S-1: A Randomized Controlled Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, open-label, controlled study that will compare the efficacy of oxaliplatin in combination with irinotecan to irinotecan alone as second-line treatment for patients with gemcitabine and S-1 refractory pancreatic cancer.

Conditions

• Pancreatic Neoplasms

Interventions

Type	Name	Description
DRUG	Irinotecan
DRUG	Oxaliplatin

Timeline

• Start date: 2015-09-01
• Primary completion: 2017-09-30
• Completion: 2017-12-31
• First posted: 2015-09-24
• Last updated: 2018-06-21

Locations

1 site across 1 country: China